New Faslodex(TM) (Fulvestrant) Data Fill 'Treatment Gap' for Women With Advanced Breast Cancer (y 2)

-- Breast cancer is the most common cancer affecting women. More than 1,150,000 new cases are diagnosed each year, and there are more than 400,000 deaths from the disease annually.(8) Approximately 20% of all women diagnosed with breast cancer have advanced disease (stage IV), where the cancer has spread to other parts of the body. The average period of survival for women with metastatic disease is 18-24 months, but this can vary widely between individual patients.(9)

AstraZeneca

-- AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of US$23.95 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.

For further information, please visit our website www.astrazenecapressoffice.com or contact:

References

1. Gradishar W, Chia S, Piccart M, on behalf of the EFECT writing committee et al. Fulvestrant versus exemestane following prior non-steroidal aromatase inhibitor therapy: first results from EFECT, a randomized, phase III trial in postmenopausal women with advanced breast cancer. Oral presentation 12 at SABCS, 15 December 2006.

2. Robertson JFR, Williams MR, Todd J et al. Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy. Eur J Cancer Clin Oncol 1989; 23 (1): 469-475.

3. Howell A, Mackintosh J, Jones M et al. The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer & Clin Oncol 1988; 24 (10): 1567-1572.

4. Robertson JFR, Osborne CK, Howell A et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma for postmenopausal women: A prospective combined analysis of two multicenter trials. Cancer 2003; 98 (2): 229-238.

5. Mauriac L, Pippen JE, Quaresma Albano J, et al. Fulvestrant (Faslodex(TM)) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. European Journal of Cancer 2003;39:1228-33.

6. Fallowfield L, Atkins L, Catt S et al. Patients' preference for administration of endocrine treatments by injection or tablets: Results from a study of women with breast cancer. Ann Oncol 2006;17:205-10.

7. Cameron DA, Camidge DR, Gait CF, Hirsch MW. Fulvestrant in the treatment of hormone receptor-positive advanced breast cancer - a cost-effective addition to the treatment sequence. Poster presentation at SABCS, 16 December 2006.

8. Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide IARC CancerBase No. 5. version 2.0, IARCPress, Lyon, 2004.

9. National Institute for Clinical Excellence (NICE). Guidance on cancer services. Improving outcomes in breast cancer. Manual update (www.nice.org.uk ).

Lynn Grant, Global PR Director, Breast Cancer, AstraZeneca, Mob: +44-(0)-7715-484-917, Email: Lynn.Grant@Astrazeneca.com, Fiona Robertson, Account Director, Shire Health, Mob: +44-(0)-781-241-4434, Email: fiona.robertson@shirehealth.com